CN102065850A - 带静电荷的鼻应用多用途产品和方法 - Google Patents
带静电荷的鼻应用多用途产品和方法 Download PDFInfo
- Publication number
- CN102065850A CN102065850A CN2009801224346A CN200980122434A CN102065850A CN 102065850 A CN102065850 A CN 102065850A CN 2009801224346 A CN2009801224346 A CN 2009801224346A CN 200980122434 A CN200980122434 A CN 200980122434A CN 102065850 A CN102065850 A CN 102065850A
- Authority
- CN
- China
- Prior art keywords
- product
- people
- nose
- ammonium salt
- nostril
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title description 7
- 239000007922 nasal spray Substances 0.000 claims abstract description 26
- 239000002537 cosmetic Substances 0.000 claims abstract description 20
- 239000000126 substance Substances 0.000 claims abstract description 16
- 239000003973 paint Substances 0.000 claims abstract description 12
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 9
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 9
- 201000009890 sinusitis Diseases 0.000 claims abstract description 6
- 229940097496 nasal spray Drugs 0.000 claims description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical class [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 17
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 12
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 10
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 10
- 150000001768 cations Chemical group 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 230000000845 anti-microbial effect Effects 0.000 claims description 5
- 229960000074 biopharmaceutical Drugs 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 235000013599 spices Nutrition 0.000 claims description 5
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 4
- 108010073771 Soybean Proteins Proteins 0.000 claims description 4
- 241000209140 Triticum Species 0.000 claims description 4
- 235000021307 Triticum Nutrition 0.000 claims description 4
- 239000003599 detergent Substances 0.000 claims description 4
- 229960005337 lysine hydrochloride Drugs 0.000 claims description 4
- 108010022355 Fibroins Proteins 0.000 claims description 3
- 108010076876 Keratins Proteins 0.000 claims description 3
- 102000011782 Keratins Human genes 0.000 claims description 3
- 230000005686 electrostatic field Effects 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- XXRYFVCIMARHRS-UHFFFAOYSA-N propan-2-yl n-dimethoxyphosphorylcarbamate Chemical compound COP(=O)(OC)NC(=O)OC(C)C XXRYFVCIMARHRS-UHFFFAOYSA-N 0.000 claims description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N protonated dimethyl amine Natural products CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 3
- 235000019710 soybean protein Nutrition 0.000 claims description 3
- 230000002939 deleterious effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 11
- 239000013566 allergen Substances 0.000 abstract description 11
- 239000011780 sodium chloride Substances 0.000 abstract description 6
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 239000003344 environmental pollutant Substances 0.000 abstract description 5
- 231100000719 pollutant Toxicity 0.000 abstract description 5
- 239000003205 fragrance Substances 0.000 abstract 1
- 230000000475 sunscreen effect Effects 0.000 abstract 1
- 239000000516 sunscreening agent Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 210000001331 nose Anatomy 0.000 description 18
- 206010020751 Hypersensitivity Diseases 0.000 description 9
- 208000026935 allergic disease Diseases 0.000 description 9
- 230000007815 allergy Effects 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000007921 spray Substances 0.000 description 7
- 240000002853 Nelumbo nucifera Species 0.000 description 6
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 6
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003068 static effect Effects 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- -1 hydroxypropyl Chemical group 0.000 description 5
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 239000000356 contaminant Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000003605 opacifier Substances 0.000 description 4
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 3
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 244000042664 Matricaria chamomilla Species 0.000 description 3
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 3
- 208000036071 Rhinorrhea Diseases 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 3
- 239000002250 absorbent Substances 0.000 description 3
- 230000002745 absorbent Effects 0.000 description 3
- 239000003139 biocide Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 208000027744 congestion Diseases 0.000 description 3
- 229960000265 cromoglicic acid Drugs 0.000 description 3
- 239000004922 lacquer Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001932 seasonal effect Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000017945 Matricaria Nutrition 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 206010070488 Upper-airway cough syndrome Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940060228 afrin Drugs 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940058060 astelin Drugs 0.000 description 1
- 229940025250 camphora Drugs 0.000 description 1
- 239000010238 camphora Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940107702 grapefruit seed extract Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960004123 mometasone furoate monohydrate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 229940089969 nasalcrom Drugs 0.000 description 1
- 229940003691 nasonex Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229960005162 oxymetazoline hydrochloride Drugs 0.000 description 1
- BEEDODBODQVSIM-UHFFFAOYSA-N oxymetazoline hydrochloride Chemical group Cl.CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 BEEDODBODQVSIM-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- LUPNKHXLFSSUGS-UHFFFAOYSA-M sodium;2,2-dichloroacetate Chemical compound [Na+].[O-]C(=O)C(Cl)Cl LUPNKHXLFSSUGS-UHFFFAOYSA-M 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Birds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
一族产品,其被设计为改善鼻窦炎和变应性鼻炎并且通过将某些化学物质与现有产品组合而产生,由此产生协同效应和减轻。化学物质产生围绕鼻子的带静电荷的场并阻止变应原或污染物进入鼻孔以引起使用者反应、疾病或不适。因此,本发明包括被应用到面部并因此围绕鼻子和鼻孔的产品,以及直接地被应用到鼻子中的那些产品。这些产品包括但不限于鼻喷雾剂、漂洗剂、洗涤剂、遮光剂、鼻带、药签(加有药品的和不加有药品的)、薄纸、小毛巾、化妆品和香料。普通的鼻喷雾剂常常包括盐水溶液。化妆品包括伪装漆或舞台演出化妆品。本发明的原理功能是,当被喷雾入鼻子或被应用到面部、鼻子或鼻孔时,阻止有害的气载颗粒进入鼻子。
Description
相关申请的交叉引用
●本申请是在2008年7月7日提交的美国临时专利申请序列号61/078,472(在下文为′472申请)的非临时副本。本申请要求通过引用以其整体并入本文的472′申请的权益和优先权。
●′472申请公开了在2004年8月3日(现在过期了)提交的标题为“ELECTROSTATICALLY CHARGED NASAL APPLICATION MULTIPURPOSE PRODUCTS AND METHOD(带静电荷的鼻应用多用途产品和方法)”的我在先的美国临时专利申请序列号60/598,462(在下文为′462申请)相同的内容。没有新的内容被添加到′462申请以产生′472申请。所述′462申请通过引用以其整体并入本文。
●本申请另外涉及1995年11月21日授权的标题为“ELECTROSTATICALLY CHARGED NASAL APPLICATION PRODUCT AND METHOD(带静电荷的鼻应用产品和方法)”的我的美国专利序列号5,468,488。该专利通过引用以其整体并入本文。
●本申请还涉及1997年10月7日授权的标题为“ELECTROSTATICALLY CHARGED NASAL APPLICATION PRODUCT(带静电荷的鼻应用产品)”的我的美国专利序列号5,674,481。该专利通过引用以其整体并入本文。
●此外,本申请涉及2005年1月18日授权的标题为“ELECTROSTATICALLY CHARGED NASAL APPLICATION PRODUCT WITH INCREASED STRENGTH(具有增加强度的带静电荷的鼻应用产品)”的我的美国专利序列号6,844,005。该专利通过引用以其整体并入本文。
发明领域
本发明涉及通过将产生能够吸引或排斥气载污染物的静电场的化学物质与另外开发用于与人类身体结合的各种普通用途的产品组合而制造的产品。一种这样的产品是与阳离子试剂组合以能够限制气载污染物流入鼻孔的目前用于其他目的的鼻喷雾剂的族。通过捕获污染物并抑制它们进入身体,这减少了气载污染物流入鼻孔。第二种产品是应用到面部的化妆品(cosmetic makeup),例如面部化妆品、小丑或舞台演出化妆品或伪装面漆。这样的产品捕获气载污染物,由此阻止进入穿戴者的鼻孔。
发明背景
在本发明中,产生静电荷的化学物质可以与不同用途的产品配对,以产生具有改进初期产品的用途和有效性的性质的新产品。这样的具有期望的静电性质的产品可以被概括地分类为:
●类型I:通过以原子水平赋予期望的性质而产生的产品。实例将是具有增加的功效或强度的新的盐水盐液体。
●类型II:通过以分子水平混合已知的化学实体赋予期望的性质而产生的产品。例如,具有增加的电荷以帮助阻止室外的气载颗粒的用于鼻子的普通遮光剂产品。
●类型III:涂药器或装置,其应用预湿润或预配剂,以用于本主题发明的产品或上述提到的现有技术中的任一种的单一用途和/或多用途。例如,用于一天使用的在可再密封的箔袋中的预湿润毡制尖端涂药器(pre-moistened felt tip applicator)。
●类型IV:上述类型中的任两种或更多种的产品的混合。
作为实例-具有提高的静电性质以对抗变态反应或传染性颗粒的透过的被抗菌增湿凝胶浸泡过的单一用途薄纸;或将从空气中过滤去室外的变应原的伪装面漆海绵涂药器凝胶等。
这些多用途产品可以被配制在介质中,介质通常与配对产品中的每一种相关或以任一方式,例如乳膏、洗剂、小毛巾或吸水纸(wipe)、化妆品或漆、喷雾剂、洗涤剂、凝胶、棉药签、泡沫药签、口罩等。
现有技术产品限于捕获基本上是造成花粉热以及类似情况的原因的气载颗粒以及杀死有害微生物或阻止它们进入鼻子。并没有将上述用途与被应用到面部或鼻区域的其他不相关产品组合。
变应性鼻炎(allergic rhinitis)是花粉热的医学名称,是由身体对空气中的被称为变应原(allergen)的微小物质的反应引起的。变应原一般是无害的,且我们一直将它们吸入和吸出。如果人遭受变态反应(allergy),那么身体认为这些变应原正在攻击系统。身体通过产生被称为组胺的化学物来抵抗,组胺使鼻孔变得刺激或发炎。变应性鼻炎一般不会产生严重的健康问题,但变应性鼻炎可以使患有其的那些人的生活非常不舒服。
变应性鼻炎的最普遍症状中的一些是淤血、发痒和/或流鼻涕、打喷嚏和后鼻滴涕。这些症状是身体对所吸入的季节性变应原或环境刺激剂的自然反应。此外,鼻炎在特定的季节期间发生或在整年中持续。变态反应症状持续多久可以取决于鼻炎的类型。鼻窦炎常常呈现相似的症状。
变态反应和鼻窦炎患者使用鼻喷雾剂可以获得减轻,且他们由下面五个种类组成:
●鼻淤血
●变态反应
●窦感染
●流鼻涕
●一般窒息
此外,喷雾剂被再分成五个主要的部分(segment):
○抗组胺剂喷雾剂
■仅凭处方
■对抗粉尘和花粉变态反应最有效
○皮质类固醇鼻喷雾剂
■仅凭处方
■靶向淤血
■炎症
■肿胀
■抗炎效果
○色甘酸钠鼻喷雾剂
■OTC
■治疗发痒的眼睛
■流鼻涕
■并不解决窒息
○减充血剂喷雾剂
■OTC
■有助于减少淤血
■减轻窒息
○盐水鼻喷雾剂/盐水洗涤剂
■全部鼻喷雾剂中最安全的
■鼻问题的预防措施
■阻止粘液聚集
■保持鼻子潮湿
其他产品被应用到面部,其他产品例如鼻带、香料、遮光剂和化妆品,化妆品例如伪装漆和面部化妆品。这些产品具有普通用途。它们被应用到非变应性的人的面部以及被应用到变态反应患者的面部。如果气载颗粒变应原可以被阻止进入鼻子和接触鼻粘膜,那么变应性鼻炎可以大大地被减轻。
发明概述
本发明是被设计为改善鼻窦炎和变应性鼻炎的症状的一组新产品,本发明是通过将某些化学物质与现有产品组合,由此产生协同效应。化学物质产生围绕鼻子的带静电荷的场并阻止变应原或污染物进入鼻孔以引起使用者反应、疾病或不适。因此,本发明包括被应用到面部并因此围绕鼻子和鼻孔的产品,以及直接地被应用到鼻子中的那些产品。这些产品包括但不限于,鼻喷雾剂、遮光剂、鼻带、药签(加有药品的和不加有药品的)、薄纸、小毛巾、化妆品和香料。普通的鼻喷雾剂常常包括盐水溶液。化妆品包括伪装漆或面部化妆品。这些仅是可以被有效地与化学物质组合的产品的类型的实例。本发明的原理功能是,当被喷雾入鼻子中或被应用到面部时,阻止有害的气载颗粒进入鼻子。
发明详述
●本发明的多用途产品具有以下性质:
●静电荷,以阻止变应原、污染物和其他污染物进入鼻孔,由此大大地减少变应性的和其他有害反应;和
●适于应用在面部上和鼻孔周围的产品的实例包括但不限于:
○鼻喷雾剂。鼻喷雾剂可用于提供变态反应和感冒的症状的减轻以及用于施用药物。通过将这些鼻喷雾剂中的一种与静电荷组合,使用者将能够减轻或治疗变态反应的症状,而同时阻止将来的变应性反应。
○伪装面漆。伪装面漆由军队在战斗时使用以便伪装他们。漆覆盖整个面部并因此被应用在鼻子周围。此漆可以用静电荷来改进以便把粉尘和其他变应原排斥在外、阻止变态反应攻击,这对军队在执行任务时极其有用。
ASTELIN是唯一被批准治疗由季节性变应原和环境刺激剂两者触发的鼻的症状的处方抗组胺剂喷雾剂。其活性成分是盐酸氮卓斯汀。非活性成分包括:
●氯化钠、
●磷酸氢二钠、
●乙二胺四乙酸二钠(edelate disodium)
●柠檬酸、
●苯扎氯铵(benzalkonium chloride)、和
●净化水(pH 6.8)。
●甘油、
●微晶纤维素、
●羧甲基纤维素钠、
●柠檬酸钠、
●柠檬酸、
●苯扎氯铵、和
●聚山梨醇酯80。
Afrin提供各种不同的治疗鼻淤血的产品。它们的活性成分是盐酸羟甲唑啉(0.05%),一种鼻减充血剂。非活性成分包括:
●苯扎氯铵、
●苄醇、
●乙二胺四乙酸二钠、
●聚乙二醇、
●聚乙烯吡咯酮(povidone)、
●丙二醇、
●磷酸氢二钠、
●磷酸二氢钠、
●樟脑、
●桉油精、
●薄荷醇、
●聚山梨醇酯80
●母菊(Chamomilla Recutita)(母菊属(Matricaria))花油(香料)、和
●羧甲基纤维素钠。
NasalCrom是具有色甘酸钠(chromolyn sodium)作为其活性成分的色甘酸钠鼻喷雾剂的实例。非活性成分包括苯扎氯铵、乙二胺四乙酸二钠和EDTA。盐水溶液鼻喷雾剂的实例以Xlear商标名销售。此处,活性成分是盐水(saline)和木糖醇。非活性成分包括碳酸氢钠和葡萄柚种子提取物。
伪装漆的实例将包括:
●二氧化钛、
●矿物油、
●石蜡、
●蜂蜡、
●巴西棕榈蜡(cornicia cerifera wax)、
●微晶蜡、
●滑石、
●尼泊金丙酯、
●玉米油、
●丙二醇、
●BHA、
●BHT、
●没食子酸丙酯、和
●柠檬酸。
伪装漆的一个可替代的实例包括:
●地蜡、
●蓖麻蜡、
●矿物油(重粘度)、
●化妆黄(Cosmetic Yellow)、
●化妆绿(Cosmetic Green)(含水的和无水的)、
●化妆黑(Cosmetic Black)、
●化妆深褐(Cosmetic Burnt Sienna)、和
●氧化钛(Atlas White)。
注意,上面列出的全部鼻喷雾剂都含有苯扎氯铵,而伪装漆中没有一种含有该物质。对于两种产品,苯扎氯铵被引入或是被增加量以使杀生(biocide)效果最大,增加阳离子皮肤粘附性质和提供更大的皮肤穿透以增强活性成分。类似地,赖氨酸盐酸盐被引入鼻喷雾剂中以作为杀生剂(biocide)和作为粘膜调节剂。此外,应当引入具有增湿效果的专用等渗成分。这些包括海带提取物和藻类提取物。
首先,引入有效量的阳离子试剂以增强使用该产品的益处。这些阳离子试剂包括但不限于:
●聚季铵盐-6
●聚季铵盐-7、
●聚季铵盐-10、
●聚季铵盐-22、
●聚季铵盐-88、
●椰油基二甲基铵羟丙基水解角蛋白、
●羟丙基三甲基铵水解大豆蛋白(hydroxypropyl thmonium hydrolyzed soy protein)、
●羟丙基三甲基铵丝蛋白(hydroxypropyl trimonium silk protein)、
●羟丙基三甲基铵小麦蛋白(hydroxypropyl trimonium wheat protein)、和
●羟丙基三甲基铵燕麦蛋白(hydroxypropyl trimonium oat protein)。
许多有效的鼻喷雾剂已经由发明人开发以清洁阻塞的窦。一种这样的喷雾剂包括作为活性成分的在水溶液中的按重量计1%的聚季铵盐-10。另一种包括在水溶液中的按重量计0.75%的聚季铵盐-6,其被认为是更有效的。
现有产品常常但不总是包括防腐剂和其他杀生物质(biocidic substance)。最终产品应含有这些物质。实例是抗微生物剂和生物治疗剂(biopharg agent)。这些中典型的分别是苯扎氯铵和赖氨酸盐酸盐。
此外,可以将上述化学物质引入吸水纸、小毛巾和湿薄纸中,它们全部用于应用到面部。
总之,以乳膏、洗剂、凝胶、液体、喷雾剂、雾、洗涤剂、药签、带、吸水纸、小毛巾、薄纸、棒的形式的诸如盐水溶液、香料、遮光剂、增湿剂、化妆品、伪装漆和外科口罩的产品或任一其他方法可以适当地与适用于预期用途的静电荷结合。
Claims (16)
1.一种通常应用于人的鼻孔或应用到人的邻近鼻区域的面部的制造的产品,
●所述产品包括各种化学物质,
●其中所述产品通过改进初始产品来产生,和
●其中所述初始产品的改善包括掺入在人的鼻孔或邻近人的鼻区域产生静电场的有效量的另外的化学物质,
●使得带相同电荷的气载颗粒从人的鼻孔或鼻区域排除出去,而带相反电荷的气载颗粒被吸引到人的鼻孔或鼻区域,
●由此减轻人的鼻窦炎或变应性鼻炎的症状。
2.如权利要求1所述的产品,其中所述产品选自由以下组成的组:
●鼻喷雾剂,
●鼻漂洗剂,
●鼻洗涤剂,
●用于应用到人的面部的香料,
●用于应用到人的面部的化妆品,
●湿的小毛巾,
●湿薄纸,和
●棒涂药器。
3.如权利要求2所述的产品,其中所述产品为伪装面漆或舞台演出化妆品。
4.如权利要求1所述的产品,其中所述产品的物理状态选自由以下组成的组:
●液体,
●乳膏,
●洗剂,
●凝胶,和
●气溶胶。
5.如权利要求1所述的产品,其中所述另外的化学物质中的至少一种为阳离子试剂。
6.如权利要求5所述的产品,其中所述阳离子试剂选自由以下组成的组:
●聚季铵盐-6,
●聚季铵盐-7,
●聚季铵盐-10,
●聚季铵盐-22,
●聚季铵盐-88,
●椰油基二甲基铵羟丙基水解角蛋白,
●羟丙基三甲基铵水解大豆蛋白,
●羟丙基三甲基铵丝蛋白,
●羟丙基三甲基铵小麦蛋白,和
●羟丙基三甲基铵燕麦蛋白。
7.如权利要求1所述的产品,其中所述另外的化学物质中的至少一种是抗微生物剂。
8.如权利要求7所述的产品,其中所述抗微生物剂是苯扎氯铵。
9.如权利要求1所述的产品,其中所述另外的化学物质中的至少一种是生物治疗剂。
10.如权利要求9所述的产品,其中所述生物治疗剂是赖氨酸盐酸盐。
11.一种鼻喷雾剂溶液,其包括阳离子试剂,使得当所述溶液被喷入人的鼻孔时,在人的鼻孔和邻近人的鼻孔处产生静电场,由此减轻有害的气载颗粒对人的影响。
12.如权利要求11所述的鼻喷雾剂溶液,其中所述阳离子试剂选自由以下组成的组:
●聚季铵盐-6,
●聚季铵盐-7,
●聚季铵盐-10,
●聚季铵盐-22,
●聚季铵盐-88,
●椰油基二甲基铵羟丙基水解角蛋白,
●羟丙基三甲基铵水解大豆蛋白,
●羟丙基三甲基铵丝蛋白,
●羟丙基三甲基铵小麦蛋白,和
●羟丙基三甲基铵燕麦蛋白。
13.如权利要求11所述的鼻喷雾剂溶液,还包括抗微生物剂。
14.如权利要求13所述的鼻喷雾剂溶液,其中所述抗微生物剂是苯扎氯铵。
15.如权利要求11所述的鼻喷雾剂溶液,还包括生物治疗剂。
16.如权利要求15所述的鼻喷雾剂溶液,其中所述生物治疗剂是赖氨酸盐酸盐。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7847208P | 2008-07-07 | 2008-07-07 | |
US61/078,472 | 2008-07-07 | ||
PCT/US2009/048180 WO2010005770A2 (en) | 2008-07-07 | 2009-06-22 | Electrostatically charged nasal application multipurpose products and method |
US12/489,185 US20090258946A1 (en) | 2008-07-07 | 2009-06-22 | Electrostatically charged nasal application multipurpose products and method |
US12/489,185 | 2009-06-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN102065850A true CN102065850A (zh) | 2011-05-18 |
Family
ID=41164517
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009801224346A Pending CN102065850A (zh) | 2008-07-07 | 2009-06-22 | 带静电荷的鼻应用多用途产品和方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090258946A1 (zh) |
EP (1) | EP2313089A4 (zh) |
JP (1) | JP2011527344A (zh) |
KR (1) | KR20110036919A (zh) |
CN (1) | CN102065850A (zh) |
AU (1) | AU2009268884A1 (zh) |
CA (1) | CA2726314A1 (zh) |
WO (1) | WO2010005770A2 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110787385A (zh) * | 2019-11-21 | 2020-02-14 | 梅玲玲 | 一种消防湿巾放置装置 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9737497B2 (en) | 1993-06-24 | 2017-08-22 | Trutek Corp. | Electrostatically charged nasal application method and product for micro-filtration |
JP2014057724A (ja) * | 2012-09-18 | 2014-04-03 | Fumakilla Ltd | 有害物質の吸入抑制製品 |
US11369578B2 (en) | 2018-11-15 | 2022-06-28 | Bluewillow Biologics, Inc. | Persistent topical antimicrobial compositions and methods of using the same |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1071015A (en) * | 1912-03-07 | 1913-08-26 | Jacob Adler | Respirator. |
US2237954A (en) * | 1939-06-30 | 1941-04-08 | William R Wilson | Nasal filter and inhaler |
US2433565A (en) * | 1946-06-21 | 1947-12-30 | Korman Alexander | Nose filter |
US2751906A (en) * | 1953-10-26 | 1956-06-26 | Mary E Irvine | Nose filters |
US2777442A (en) * | 1955-04-11 | 1957-01-15 | Zelano Joseph | Nasal filter |
US3145711A (en) * | 1961-12-08 | 1964-08-25 | Beber Arthur | Disposable nasal filter |
US3513839A (en) * | 1968-01-02 | 1970-05-26 | Matthew Vacante | Valved nose filter |
US4052983A (en) * | 1975-09-04 | 1977-10-11 | Bovender Coy R | Nasal filter |
US4030491A (en) * | 1975-10-31 | 1977-06-21 | Alvin Mattila | Nasal filter |
US4267831A (en) * | 1979-09-24 | 1981-05-19 | Aguilar Rogelio M | Nasal air filter and medicament dispenser device |
US4401117A (en) * | 1981-02-23 | 1983-08-30 | Hyman Gershuny | Therapeutic appliance |
DE3509857C2 (de) * | 1984-03-19 | 1994-04-28 | Toyo Boseki | Elektretisiertes Staubfilter und dessen Herstellung |
US4874659A (en) * | 1984-10-24 | 1989-10-17 | Toray Industries | Electret fiber sheet and method of producing same |
US5674481A (en) * | 1993-06-24 | 1997-10-07 | Wahi; Ashok L. | Electrostatically charged nasal topical application product |
US20030223934A1 (en) * | 2002-06-04 | 2003-12-04 | Trutek Corp | Electrostatically charged nasal application diagnotic product and method |
US6844005B2 (en) * | 2002-02-25 | 2005-01-18 | Trutek Corp | Electrostatically charged nasal application product with increased strength |
US5468488A (en) * | 1993-06-24 | 1995-11-21 | Wahi; Ashok L. | Electrostatically charged nasal application product and method |
US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
JPH09157152A (ja) * | 1995-12-06 | 1997-06-17 | Lion Corp | 花粉症予防剤 |
GB9903926D0 (en) * | 1999-02-19 | 1999-04-14 | Procter & Gamble | Cosmetic compositions |
US6531142B1 (en) * | 1999-08-18 | 2003-03-11 | The Procter & Gamble Company | Stable, electrostatically sprayable topical compositions |
JP2003001100A (ja) * | 2001-06-04 | 2003-01-07 | Microcapsules Technologies | 陽イオン性マイクロカプセルを製造する方法 |
US20040071757A1 (en) * | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
CN1297275C (zh) * | 2002-11-12 | 2007-01-31 | 爱尔康公司 | 抗过敏剂和类固醇用于治疗过敏性鼻炎的用途 |
EP1701677A4 (en) * | 2003-08-20 | 2011-12-14 | Ashok L Wahi | ELECTROSTATICALLY CHARGED NASAL APPLICATION PREPARATION WITH INCREASED STRENGTH |
WO2008052031A2 (en) * | 2006-10-24 | 2008-05-02 | Alcon Research, Ltd. | 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions |
-
2009
- 2009-06-22 CN CN2009801224346A patent/CN102065850A/zh active Pending
- 2009-06-22 JP JP2011517457A patent/JP2011527344A/ja active Pending
- 2009-06-22 KR KR1020117002186A patent/KR20110036919A/ko not_active Application Discontinuation
- 2009-06-22 CA CA2726314A patent/CA2726314A1/en not_active Abandoned
- 2009-06-22 EP EP09794956A patent/EP2313089A4/en not_active Withdrawn
- 2009-06-22 US US12/489,185 patent/US20090258946A1/en not_active Abandoned
- 2009-06-22 AU AU2009268884A patent/AU2009268884A1/en not_active Abandoned
- 2009-06-22 WO PCT/US2009/048180 patent/WO2010005770A2/en active Application Filing
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110787385A (zh) * | 2019-11-21 | 2020-02-14 | 梅玲玲 | 一种消防湿巾放置装置 |
Also Published As
Publication number | Publication date |
---|---|
WO2010005770A2 (en) | 2010-01-14 |
AU2009268884A1 (en) | 2010-01-14 |
WO2010005770A3 (en) | 2010-03-25 |
WO2010005770A8 (en) | 2010-09-16 |
EP2313089A2 (en) | 2011-04-27 |
CA2726314A1 (en) | 2010-01-14 |
US20090258946A1 (en) | 2009-10-15 |
KR20110036919A (ko) | 2011-04-12 |
EP2313089A4 (en) | 2012-10-24 |
JP2011527344A (ja) | 2011-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20060122082A1 (en) | Foam/spray producing compositions and dispensing system therefor | |
RU2010123052A (ru) | Авенантрамидсодержащие композиции | |
CN113304102A (zh) | 用于局部伤口治疗的制剂 | |
US20100055152A1 (en) | Antihistamine and antihistamine-like nasal application, products, and method | |
KR20180032644A (ko) | 코 조성물 | |
CN102065850A (zh) | 带静电荷的鼻应用多用途产品和方法 | |
EP0125634A1 (de) | Verwendung einer sekretolytisch wirkenden Substanz zur Herstellung eines Antischnarchmittels und zur Bekämpfung des Schnarchphänomens | |
WO2009036714A1 (de) | Zusammensetzung für wundbehandlungen enthaltend zumindest silber und harnstoff | |
CN102861206A (zh) | 皮肤粘膜杀菌消毒气雾剂及其制备方法 | |
CH662734A5 (de) | Antischnarchmittel. | |
Bras et al. | Evaluation of the acute dermal exposure of the ethanolic and hexanic extracts from leaves of Schinus molle var. areira L. in rats | |
CN109195592A (zh) | 用于保持眼睑卫生的组合物、工具套件及方法 | |
US7807190B2 (en) | Methods for eradicating lice and fleas from a host | |
WO2008042557A2 (en) | Formulation and method for a shampoo for animals | |
JP2001240547A (ja) | 花粉症抑制剤 | |
CN104274633A (zh) | 一种清洁护鼻的组合物 | |
CN102088964B (zh) | 带静电荷的多功能鼻应用产品 | |
JP2012509250A (ja) | 抗ヒスタミン及び抗ヒスタミン様経鼻適用製品及び方法 | |
WO2022053412A1 (en) | Compositions for preventing infection | |
CN103918733B (zh) | 一种宠物除菌防跳蚤粉 | |
JP2005281315A6 (ja) | 水性薬理組成物 | |
CN109966311A (zh) | 一种眼睑用消毒液、消毒湿巾和消毒湿巾包装袋 | |
BR102012012074A2 (pt) | Adjuvantes atenuantes dos efeitos de irritação ocular em formulações para proteção vegetal e animal | |
CN117083057A (zh) | 用于预防感染的组合物 | |
CA3204015A1 (en) | Formulations of a prophylactic nasal spray and methods of use and manufacture thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110518 |